Table 1.

Trial Characteristics

					Treatment Group (n = 4598)			Placebo Group (n = 2313)
Source	Trial Name/Registry Number	Disease Indicationa	Permitted Concomitant Systemic Therapyb	Duration of Placebo- Controlled Trial, wks	Treatment (Dose)c	No. of Patients	Patient-years follow-up	No. of Patients	Patient-years follow-up
Mease et al, 200547	Study M02-518 / NCT00646386	PsA	MTX (≤30 mg/wk) or prednisone (≤10 mg/day) at stable dose; rescue therapy after 12 wks with DMARDS or corticosteroids	24	Adalimumab (40 mg eow)	151	66.8	162	71.1
Gordon et al, 200646	Study M02-528 / NCT00645814	PsO	None	12	Adalimumab (40 mg eow) Adalimumab (40 mg weekly)	45 50	10.2 11.2	52	11.8
Genovese et al, 200757	Study M02-570 / NCT00646178	PsA	MTX (≤30 mg/wk) or prednisone (≤10 mg/day), or other DMARD at stable dose	12	Adalimumab (40 mg eow)	51	11.8	49	10.8
Menter et al, 200850	Study M03-656 / NCT00237887	PsO	None	16	Adalimumab (80 mg at wk 0, then 40 mg      eow starting at wk 1)	814	250.4	398	120.7
Saurat et al, 200851	CHAMPION / Study M04-716 / NCT00235820	PsO	None	16	Adalimumab (80 mg at wk 0, then 40 mg      eow starting at wk 1) MTX (7.5 mg, increased as needed and      as tolerated to 25 mg weekly)d	108 110	34.7 34.8	52	16.3
Akihiko et al, 201078	Study M04-688 / NCT00338754	PsO	None	24	Adalimumab (80 mg at wk 0, then 40 mg      eow starting at wk 1) Adaliumumab (40 mg eow) Adalimumab (80 mg eow)	38 43 42	16.3 17.2 17.9	46	19.1
Unpublished41	Study C87040 / NCT00245765	PsO	None	12	Certolizumab pegol (400 mg at wk 0,      then 200 mg every 2 wks) Certolizumab pegol (400 mg every 2 wks)	59 58	Unknown	59	Unknown
Mease et al, 200048	Study 20021630	PsA and PsO	MTX (≤25 mg/wk) or prednisone (≤10 mg/day) at stable dose	12	Etanercept (25 mg twice weekly)	30	6.5	30	6.1
Gottlieb et al, 200352	Study 20021632	PsO	None	24	Etanercept (25 mg twice weekly)	57	23.6	55	14.5
Leonardi et al, 200342	Study 20021639	PsO	None	12	Etanercept (25 mg weekly) Etanercept (25 mg twice weekly) Etanercept (50 mg twice weekly)	160 162 164	34.3 34.6 35.8	166	34.9
Mease et al, 200449	NCT00317499	PsA	MTX (≤25 mg/wk) or prednisone (≤10 mg/day) at stable dose	24	Etanercept (25 mg twice weekly)	101	81.0	104	59.2
Papp et al, 200544	Study 20021642	PsO	None	12	Etanercept (25 mg twice weekly) Etanercept (50 mg twice weekly)	196 194	42.9 42.6	193	41.0
Tyring et al, 200755	NCT00111449	PsO	None	12	Etanercept (50 mg twice weekly)	312	68.8	306	65.9
van de Kerkhof et al, 200843	NCT00333034	PsO	None	12	Etanercept (50 mg weekly)	96	Unknown	46	Unknown
Kavanaugh et al, 200945	NCT00265096	PsA	Stable dose of MTX, prednisone, or NSAIDS	24 with early escape at week	Golimumab (50 mg every 4 wks) Golimumab (100 mg every 4 wks) All golimumabe	146 146 343	62 67 142	113	42
Gottlieb et al, 200458	SPIRIT / NCT00230529	PsO	NSAIDS	30	Infliximab (3 mg/kg at wks 0, 2, 6) Infliximab (5 mg/kg at wks 0, 2, 6)	98 99	56 58	51	20.5
Antoni et al, 200556	IMPACT	PsA	MTX or other DMARD at stable dose	16	Infliximab (5 mg/kg at wks 0, 2, 6, 14)	52	16	51	16
Antoni et al, 200540	IMPACT 2 / NCT00051623	PsA	MTX (≤25 mg/wk) or prednisone (≤10 mg/day) at stable dose	24 with early escape at wk 16	Infliximab (5 mg/kg at wks 0, 2, 6, 14, 22) All infliximabf	100 150	45 53	97	37
Reich et al, 200554	EXPRESS I / NCT00106834	PsO	NSAIDS	24	Infliximab (5 mg/kg at wks 0, 2, 6, 14, 22)	298	135	76	33
Menter et al, 200753	EXPRESS II / NCT00106847	PsO	NSAIDS	14	Infliximab (3 mg/kg at wks 0, 2, 6) Infliximab (5 mg/kg at wks 0, 2, 6)	313 314	85 85	207	54

^aPsA = psoriatic arthritis; PsO = plaque psoriasis

^bMTX = methotrexate; DMARDS = disease-modifying antirheumatic drugs; NSAIDS = non-steroidal anti-inflammatory drugs

^ceow = every other week

^dNot included in meta-analysis.

^eAll golimumab group includes all patients who received at least one dose of study drug.

^fAll infliximab group includes all those that received at least one dose of study drug.